6. Overview of studies on topical calcineurin inhibitors: investigator‐rated good/excellent control.

Study	Comparison	Investigator‐rated good/excellent control in RR (95% CI)	Comments
Schnopp 2002	Tacrolimus ointment versus mometasone furoate	No data regarding the primary outcome investigator‐rated good/excellent control	Within‐patient study
Katsarou 2012	Tacrolimus ointment versus mometasone furoate	No data regarding the primary outcome investigator‐rated good/excellent control	Improvement was reported separately for subcategories of clinical signs
Krejci‐Manwaring 2008	Tacrolimus ointment versus vehicle	No data regarding the primary outcome investigator‐rated good/excellent control	‐
Pacor 2006	Tacrolimus ointment versus vehicle	RR 29.0 (95% CI 1.9 to 443.25)	‐
Belsito 2004	Pimecrolimus cream versus vehicle	RR 1.53 (95% CI 0.99 to 2.36)	‐
Hordinsky 2010	Pimecrolimus cream versus vehicle	RR 1.28 (95% CI 0.99 to 1.66)	‐
Bauer 2012	Pimecrolimus cream versus vehicle	No data regarding the primary outcome investigator‐rated good/excellent control	‐
Baskan 2005	Pimecrolimus cream versus vehicle	No data regarding the primary outcome investigator‐rated good/excellent control	‐
Cherill 2000	Pimecrolimus cream versus vehicle	No data regarding the primary outcome investigator‐rated good/excellent control	‐

CI: confidence interval.

RR: risk ratio.